

Index

- n-Acetyl-n-methyl-colchicine (Colcemid), 119, 125, 135
- Acid phospholipids, 116
- Acidic structural proteins, 308
- Adventitial layer of vasculature, 161
- Age, elastin and, 238, 305
- Alanine, 225
- Aldehydblau, 276
- Aldehyde Blue, 276
- Aldehyde-fuchsin stain, 275–276
- Aldehyde Green, 276
- Aldol condensate, 222
- Alpha antiprotease, 260–261; cigarette smoke and, 256–257
- Alpha₁-antitrypsin, deficiency of, 248–249
- Alveolar macrophage elastase, 254–256
- α -Aminoacetonitrile-HCl, 229
- Amino acid composition
 - of desmosine cross-linked peptides, 225–226
 - of elastins, 105, 106, 196–197, 219, 221–222, 272, 282
 - of proteoglycan, 35–37
- Amino-1-hydroxy-propane-1,1-diphosphonic acid (ABDP), 118–120
- β -Amino-propionitrile, 195–196, 227–229
- Anticoagulant activity of aorta proteoglycan, 39
- Anulus fibrosis, 17
- Aorta
 - chemical determinations for, 72–73
 - distention of, 83–84
 - elastin in, 245–246
 - extraction techniques for, 30–41
 - fixation of, 70–71
 - glycosaminoglycans in, 28–30
 - hemodynamic function of, 92–93
 - histological fixation of, 69
 - proteoglycans in, 30–41
 - anticoagulant activity of, 39
 - bovine, 37–39
 - collagen orientation and, 54–55
 - mechanical behavior of, 54
 - rabbit, 37
 - transmural gradients of connective tissue of, 84–85
- Arterial collagen, 159–161
- Arterial intima, thickened, 293, 295–299
- Arterial lesions
 - collastin in; *see* Collastin, in arterial lesions
 - staining of, differential, 59–60
- Arterial walls, quantitation techniques for histological sections of; *see* Histological sections, quantitation techniques for
- Arteries
 - in children versus adults, 295
 - disease in; *see* Arteriosclerosis; Atherosclerosis, fibrous-type
 - intimal layer of, 159
 - medial layer, 159–161
 - solvent dyeing of, 305–306
 - staining of, differential, 59–60

- Arteries (*cont.*)
see also entries beginning Arterial
- Arteriosclerosis, 238; elastin in, 305
- Ascorbic acid, 29
- Atherosclerosis, fibrous-type, 95–136
 amino-hydroxy-propane-diphosphonic acid, 118–120
 azacycloheptane-2,2-diphosphonic acid (AHDP), 118–120, 125, 131
 calcification in, 116–117
 calcium homeostasis and, 133–135
 calcium ions and, 238–239
 Colcemid and, 119, 125, 135
 collagen in, 104, 161–163
 connective tissue alteration in, primary versus secondary effect in, 149
 diet in, 119–130, 149–150
 biochemical aspects of, 120–127
 histological aspects of, 127–131
 morphological aspects of, 131–134
 elastica and, 100
 elastica interna and, 284–286
 elastin and, 105, 106, 238
 enzymes and, 115
 ethane-hydroxy-diphosphonic acid (EHDP), 118–120, 125–133
 exercise and, 125, 136, 148
 glycosaminoglycans and, 29
 La Cl₃ and, 125
 lanthanum and, 119, 129, 132, 135
 lipids in, 104
 methyl ThCa and, 119, 125
 morbidity and mortality and, 117
 myointimal cells and, 297–299
 platelets and, 115
 proteoglycans and, 53
 proteolysis and, 149
 treatment of, 117–133
 Vinblastine and, 135
see also Fibrous plaques in atherosclerosis
- Autofluorescence of collagens, 279
- Autoradiograph, 100, 102
- Azacycloheptane-2,2-diphosphonic acid (AHDP), 118–120, 125, 131
- Basement membrane
 banded fiber attachment to, 171–172
 collagen and, 156, 159, 171–172, 180, 268
 elastica interna and, 286
 of lung, 254
- Birefringent layer, 293
- Bleomycin-induced pulmonary fibrosis, 199, 204, 205
- Blood
 monocytes, 256
 proteoglycans in, bovine, 20
- Blood vessels, hemodynamic function of, 92–93
- Brain, chondroitin sulfate in, 19–20
- Cadmium-induced interstitial pulmonary fibrosis, 204
- Calcification, 116–117
 elastin and, 238
 fibrous lesions and, 100
- Calcium ions
 antagonists of, 119
 atherosclerosis and, 133–135, 238–239
 connective tissue and, 115–117
 fibrous lesions and, 100
 pathobiochemistry of, 115–117
- Cardiac lesions, collagen and, 288
- Cardiovascular disease, morbidity and mortality and, 117
- Cartilage
 collagen in, 26
 proteoglycans and, 16–17
- Cesium chloride density gradient, 9–10
- Chemical analysis, 58–59, 72–73;
 stereologic determinations compared with, 86–88
- Cholesterol content, 29
 elastin and, 107–108
 fibrous plaques and, 100, 104, 107–108
 serum levels of, 117–118
- Chondroitin sulfate, 8–9, 14, 19, 20, 28–31, 39
- Chondroitinase ABC sensitive digestion, 34–35
- Chondroitinase ABC sensitive proteoglycans, 29–30
- Chondrosarcoma proteoglycan, Swarm rat, 34, 54
- Cigarette smoke
 elastin degradation and, 259
 elastin synthesis and, 256–257

- emphysema and, 256–257, 259, 261
- Colcemid (n-acetyl-n-methyl-colchicine), 119, 125, 135
- Collagen, 153–163
- acidic component, 169
 - antigenic properties of, 104–105
 - aorta proteoglycans and orientation of, 55–56
 - arterial, 159–161
 - in atherosclerosis, 161–163
 - autofluorescence of, 279
 - basement membrane; *see* Basement membrane, collagen and
 - birefringent layer, 293
 - bleomycin-induced interstitial pulmonary fibrosis, 205
 - calcification of, 117
 - cardiac abnormalities and, 288
 - in cartilage, 26
 - chemical determinations of, 72–73
 - in children with abnormalities of heart, 288
 - cross striations in, 168–169
 - crosslinkage of, 224
 - dye binding of, 290–291
 - elastica stains, binding of, 273, 284–299
 - elastin fibers and, structural differences between, 178–179
 - endothelial cell production of, 170–171
 - estimation of, 74
 - fibers, 67
 - 40,000 dalton molecule, 171
 - glycosaminoglycan interaction with, 24–25
 - heteropolyacid binding by, 279
 - interstitial, 153, 155
 - interstitial pulmonary fibrosis and, 198–201
 - intimal layer, 159
 - in intimas, thickened, 293
 - linkage of, 169; *see above* crosslinkage
 - lipids and, affinity for, 104
 - in lungs, distribution of, 216
 - measurement of, 189–190
 - morphologic form and functional role of, 169–170
 - orcein stain and, 273
 - organization form of, 169–170
 - in plaques, 104–105, 111
 - proteoglycan interaction with, 24–25
 - as gel system, 29
 - nutrient and water transportation and, 29–30
 - pulmonary volume-pressure curve and, 188
 - resorcin-fuchsin stain binding by, 271–273, 287–291
 - staining technique for, 80–81, 178, 273, 284–299
 - stereologic versus chemical determinations of, 86
 - turnover rate of, 112–113
 - types of, genetically distinct, 104, 153–163
 - ratio of type III:type I, 288
 - type-specific antibodies and, 162–163
 - type II, 156
 - type III, 156, 288, 294
 - type V, 158
 - type VI, localization of, 169
 - visualization of, 308
- Collagen-vascular disease, 197
- Collagenase, lungs treated with, 190–192
- Collastin, 275
- in arterial lesions, 291–296
 - in adults, 294–296
 - histochemistry and, 293–294
 - history of, 291–293
 - fluorescence microscopic distinction of, 279–280
 - in infants, 287–291
 - staining technique for, 279–280
- term, 273
- Connective tissue
- calcium and pathobiochemistry of, 115–117
 - organization of, in lungs, 216
 - in plaques, 97, 111–115
 - proteoglycans in, function of, 21–28
 - synthesis and secretion of, calcium ions in, 115–116
 - types of, in lungs, 178
- Contour method, 61, 62, 73–79, 85, 88–89
- advantage of, 78–79
 - application of, 65
 - optimum grid size for, 78
- Controlled pressure perfusion fixation, 70–71
- Copper deficiency, 196, 226–227

- Coronary fibrous plaques, 133
- Corticosteroid therapy, elastin and, 252–253
- Cortisol, 29
- Cross-sectional surfaces, measurement techniques for, 61–62
- Dermatan sulfate**, 9, 19, 20, 29–31, 39, 41
cholesterol and, 29
in fibrous plaques, 108–109
isolation and purification of, 18–19, 31
- Dermis**
collagen in, 26
proteoglycan in, 26
solvent dyeing of, 304–308
- Desmosine**, 221–226
in lung disease, chronic obstructive, 259
smokers and, 259
- Desmosine cross-linked peptides**, 225–226
- Desmosine peptides**
categories of, 225
cross-linked, 225–226
sequencing data for, 226
- Dexamethasone**, 246
- Diet**
in atherosclerosis, 119–133, 149–150
biochemical aspects of, 120–127
histological aspects of, 127–131
morphological aspects of, 131–133
in fibrous plaque formation, 112
lipids and, 97–98
- Digitizer computer**, 63–65; semidiagrammatic drawing of, 63
- Digitizing plate**, contour tracing on, 78–79
- Disease states**
elastin and, 237–239
proteoglycans and, 16, 26
- DNA**, 72
- Dye binding**
by collagen, 290–291
organic solvents in, 300–304
by reticulum fibers, 290–291
- Elastase**, 113–114
alveolar macrophage and, 254–256
basement membrane collagen
degradation by, 268
in emphysema, 196, 253–254
imbalances between, 260–261
proteolytic damage and, 253–256
in lung, 190–192, 250–253
monocyte synthesis of, 255–256
neutrophil, 253–254
staining techniques for, 331
- Elastase-like enzymes**, 256
- Elastic fibers**, 180–181
function and orientation of, 245
histologic aspects of, 218
morphologic orientation of, 245
protein components of, 217
staining techniques for, 178, 218
- Elastic tissue**, chemical concepts of, history of, 281–282
- Elastica**
atherosclerosis and, 100
calcification of, 116
degradation of, 114–115
plaque, 108
- Elastica interna**, 284–287, 292–293
- Elastica stains**, 269–310
aldehyde-fuchsin, 275–276
collagen and, 272, 284–299
definitions of, 270
early, 280–281
elastin core and, 280–284
ethanol and, 300–301
histochemistry of, 270–276
history of, 270–276
orcein, 273–275
reticulum fiber uptake of, 272
Schwalbe's sheaths and, 282–284
solvents and, 300–301
Verhoeff's iron hematein, 276–279
- Elastin**, 217–240
age and, 238, 305
amino acid composition of, 105, 106, 219, 221–222, 272, 282
area surrounding, 224–225
arteriosclerotic lesions and, 305
assays for degradation products of, 257–259
in atherosclerosis, 238
biosynthesis of, 235–237
calcification and, 238
calcium ion binding to, 116

- chemical determinations of, 72–73
 - cholesterol and, 107–108
 - cigarette smoke and synthesis of, 256–257
 - collagen fibers, structural differences between, 178–179
 - corticosteroid therapy and, 252–253
 - crosslinks of, 221–226
 - biosynthesis of, 222–226
 - degradation of, assays for, 257–259
 - smoking and, 259
 - developmental stage and, 246
 - disease state and, 237–239
 - elastic behavior and, 237, 239
 - in emphysema, 196–197, 249–253, 257–260
 - fibers, 67
 - in fibrous plaques, 105–111
 - fluorescence microscopic distinction of, 279–280
 - fluorescent stains for, 331–332
 - formation of, scheme for, 224
 - half-life for, 112, 113
 - hypothesis of splitting or duplication of, 292–293
 - immunogenicity and, 257–260
 - isolation of, 219
 - lathyrism and, 226–229, 244–246
 - lipid binding and, 107–108
 - in lung
 - aorta versus, 245–246
 - measurement of, 189–190
 - ¹⁴C-lysine-labeled, 221–223
 - model of, 234
 - morphology of, 218
 - normal, 107
 - obstructive lung disease and, chronic, 259
 - orcein stain and, 273–274
 - peptides in, sequences of, 234
 - physical and chemical properties of, 218–219
 - proteoglycans and, 55–56
 - proteolytic attack on, 238–239
 - pulmonary, 249–253
 - purification of, 272
 - quantification method for, 252
 - resorcin-fuchsin stain for, specificity of, 271
 - role of, 237
 - 70,000 dalton protein of, 235–236
 - 73,000 dalton protein of, 236
 - soluble, 229–230, 234
 - forms of, 236–237
 - isolation of, 227–228
 - species differences, 246
 - staining techniques for, 80–81, 279–280, 331–332
 - stereologic versus chemical determinations for, 86
- Elastin cores, history of, 280–284
- Electrophoresis, 159
- Emphysema, 195–197, 247–261, 268
 - alpha antiprotease and, 260–261
 - alpha₁-antitrypsin and deficiency of, 248–249
 - cigarette smoke and alpha antiprotease and, 256–257
 - connective tissue framework of lung and its mechanical behavior and, 191–192
 - deaths caused by, 247
 - definition of, World Health Organization, 248
 - elastase and, 196, 250–253, 260–261
 - imbalances of, 260–261
 - elastin and, 196–197, 249–253, 257–260
 - history of, 247–249
 - microscopically versus chemically determined, 252
 - neutrophil, 253–254
 - pathophysiologic pathways to, 260–261
 - proteolytic damage in vivo, 253–256
 - by alveolar macrophage, 254–256
 - by neutrophil, 253–254
- Endothelial cells
 - collagen production by, 170–171
 - transformation theory of, 298–299
- Enzymes
 - in atherosclerosis, 115
 - digestion by, proteolytic, 12
 - in emphysema treatment, 195
- Ethane-1-hydroxy-1,1-diphosphonic acid (EHDP), 118–120, 125–133, 135
- Ethanol, 300–301
- Exercise, atherosclerosis and, 125, 136, 148
- Extracellular matrix, methods to study, 5

- Fibronectin, 254, 268
- Fibrosis
 measurement of, 215
 morphometric index of, 215
- Fibrous plaques in atherosclerosis, 161
 binding of secondary proteins and, 105, 107, 116
 calcification of, 100
 calcium and, 100
 cholesterol and, 100, 104, 107–108
 collagen and, 104–105, 111
 composition of, 99–111
 biochemical aspects of, 104–111
 morphological aspects of, 99–104
 connective tissue in, 97, 111–115
 degradation of, 113
 formation of, 111–113
 coronary, 133
 diet in formation of, 112
 elastica and, 108
 elastin in, 105–111
 cholesterol and, 107–108
 encapsulated, autoradiograph of, 100
 formation of, processes leading to, 95–96
 glycoproteins and, 99–100, 110–111
 glycosaminoglycans and, 99–100, 108–110, 112
 lipids and
 depositions of, 100
 detectable, 101–104
 in diet, 97–98
 proteoglycans in, 109, 110
 regression of, 97–98, 118, 150–151
see also Atherosclerosis, fibrous-type
- Fixation of tissue, 67–71; sampling procedures and, 70–71
- Fluorescence microscopy, elastin versus collastin in, 279–280
- Fluorescent stains for elastin, 331–332
- Gelatinoids, 282
- Glial cells, proteoglycans and, 20
- Glycoproteins
 in fibrous plaques, 99–100, 110–111
 varieties of, 110
- Glycosaminoglycans
 aorta, 28–30
 atherosclerosis and, 29
 biosynthesis of, 7–9
 collagen interaction with, 24–25
 fibrous plaques and, 99–100, 108–110, 112
 glycosaminoglycan interaction with, 23–24
 lanthanum and, 129
 lipoprotein interaction with, 25
 osmotic behavior of, 23
 physiologic function in connective tissue of, 21–28
 secretion of, 112
 structure of, repeating, 6
 synthesis of, 29, 112; *see above*
 biosynthesis of
 types of, 28
- Gomori trichrome aldehyde, 67, 80
- Hemodynamic function of blood vessels, 92–93
- Heparin synthesis, 9, 20–21, 29, 39
- Heteropolyacids, collagen binding of, 279
- Hewlett-Packard system, 45, 63
- Hexuronic acid, 35
- Histochemistry, staining in; *see* Staining techniques
- Histological sections, quantitation techniques for, 57–89, 92–93
 for aorta, 69, 83–84
 chemical determinations and, 72–73
 collagen and, 86
 contour method of; *see* Contour method
 distention in, effects of, 70, 83–84
 elastin and, 86
 fixation in, effects of, 67–70
 sampling procedures and, 70–71
 introduction to, 57–60
 line method; *see* Line method
 linear orientation of surfaces in, 84
 materials and methods for, 61–73
 morphometric methods, comparison of various, 57–59, 73–79
 nuclei and, 86–87
 objective of study of, 57
 point counting; *see* Point counting method
 projector-digitizer-computer system and, 60

- sampling, 84–85
 section thickness in, 66–67, 82–84
 staining in, 66–67; *see also* Staining techniques
 differential, 59–60
 effects of, 80–81
 standard deviations and, 85
 stereologic analysis in
 chemical determination versus, 86–88
 principles of, 57–59, 61–66
 Histological staining; *see* Staining techniques
 Hormonal changes, 29
 Hyaluronic acid, 7, 11–13, 37–39
 binding region on proteoglycans, 11–13
 proteoglycan interaction with, 37–39
 Hydroxyproline, 189, 272
- Immunogenicity of elastin in emphysema, 257–260
 Immunologic injury, aorta
 glycosaminoglycans and, 29
 Infants, collastin in, 287–291
 Ion exchange resin, proteoglycans as, 22–23
 Ion transport, proteoglycans and, 22–23
 Internal elastic membranes, 284–287;
 hypothesis of splitting or duplication of, 292–293
 Interstitial pulmonary fibrosis; *see* Pulmonary fibrosis, interstitial
 Intima cushions, physiologic, 295–296
 Intimal layer, arterial, thickened, 293, 295–299
 Iron hematoxylin, 277
 Isodesmosine, 221
 Isolan Blue RLS, 331
 Isolan series of dyes, 302–303
- Keratan sulfate, 7, 13–16, 19
 oligosaccharide and, 14–16
 proteoglycan region rich in, 13–17
- La Cl₃, 125
 Lanthanum, 119, 129, 132, 135
 Lathyrism, 226–229; elastin and, 226–229, 244–246
 Lathrogen, 196
 Line method, 61, 73–79, 85
 application of, 65–66
 optimum grid size for, 77–78
 Link protein, 12–13
 Lipids
 collagen and, affinity for, 104
 plaques
 and deposition of, 100
 detectable, 101–104
 diet and, 97–98
 elastin and, 107–108
 pool of, 108
 staining of, 102
 Lipoprotein
 glycosaminoglycan interaction with, 25
 proteoglycan interaction with, 25
 Lung disease
 index of, 208
 obstructive, chronic, 259
 see also Emphysema; Pulmonary fibrosis, interstitial
 Lungs
 bronchovascular network of, 181
 chord compliance in, definition of, 185
 collagen in, 188–190
 distribution of, 216
 measurement of, 189–190
 collagenase-treated, 190–192
 connective tissue framework of, 178–182
 evaluation of integrity of, 189–190
 organization of, 216
 disease of; *see* Lung disease
 elastase and, 190–192, 250–253
 elastic properties of, measurement of, 182–186
 elastin in, 245–246
 measurement of, 189–190
 quantification method for, 252
 expiratory reserve volume of, 185
 functional residual capacity of, 185
 hysteresis ratio, 208
 interstitial network in, 181
 mechanical behavior of, 177–209
 morphometric index of fibrosis, 215
 pleura, 181
 pleural pressure, measurement of, 183
 quasi-static compliance of, 185

- Lungs (*cont.*)
 residual volume of, 185
 Setnikar-Mead theory, 190, 194–195
 solvent dyeing of, 306–307
 static transpulmonary pressure, 183
 transpulmonary pressure, 196
 viscoelastic properties of, 186–187, 208, 216
 vital capacity of, 185
 volume, measurement of, 183–186, 192–193
 volume-pressure relations of, 183–186, 204–205
 connective tissue framework as
 determinant of, 186–188, 190–195
 evaluation of, 187
 in vitro, 190–191
 in vivo, 191–195
¹⁴C-Lysine-labeled elastin, 221–223
 Lysinonorleucine, 221, 223
 Lysyl oxidase, 226–227
- Macrophages, elastase in, 114, 254–256
 Mannose-rich asparagine linked glycopeptide, 14
 Matrix, extracellular, methods to study, 5
 Medial layer, arterial, 159–161
 Methyl-ThCA, 119, 125
 Methylated derivative of 2-thiophene carboxylic acid (Methyl-ThCA), 119, 125
 Microfibril, 217–218
 Microscopy, dyes in future of, 309–310
 Monocyte, elastase synthesis by, 255–256
 Morbidity, cardiovascular disease, 117
 Morphometric index of fibrosis, 215
 Mortality
 cardiovascular disease and, 117
 emphysema and, 247
 Mucolytic enzymes, 114
 Musculo-elastic layer, 296–299
 Myelin sheaths, stains for, 278–279
 Myoendothelial cells, 296–297
 Myofibrils, 296–297
 Myointimal cells, 297–299
- Nasal septa proteoglycan, 34
 Niagara Blue-Fast Wool Red, 331
 Nuclei, 66–67, 86–87
 Nucleus pulposus, 18
 Nutrient transportation, 29–30
- Obstructive lung disease, chronic, 259
 Oligosaccharides, 14–16
 Orcein stain, 273–275, 330
 for collagen, 273
 for elastin, 273–274
 Organic solvents, 300–304
 Ovarian follicular fluid, proteoglycans in, 20
- Papain, 195
 Pattern recognition, 58–59
 DM-Penicillamine, 195–196
 Peptides in elastin, 234
 Perfusion fixation, 70–71
 Phospholipids, 116
 Phosphomolybdic acid (PMA), 279–280, 331–332
 Phosphotungstic acid (PTA), 279
 Picro-Sirius Red F3BA, 290–291
 Plaque, fibrous; *see* Fibrous plaques in atherosclerosis
 Platelet
 aggregation, aorta proteoglycan, 39
 enzymes in atherosclerosis, 115
 proteoglycans in, 20, 39
 Pleura, 181
 Pleural pressure, measurement of, 183
 Point counting method, 61–62, 73–79, 85
 application of, 66
 optimum grid size in, 77
 Premetallized dyes, 302–303
 Procollagen, 111–112
 Projector-digitizer-computer system, 60, 81
 Protease with elastolytic activities, 114
 Proteins, acidic structural, 308
 Proteoglycans, 5–41
 aggregates
 formation of, 37–39, 54
 structural analysis of, 11–16
 amino acid composition of, 35–37
 in anulus fibrosus, 17
 aorta; *see* Aorta, proteoglycans in atherosclerosis and, 53
 in blood, bovine, 20
 in brain, 19–20

- carbohydrate linkage region of, 7
- cartilage and, 16–17, 26
- chondroitin sulfate region of, 14
- chondroitinase ABC sensitive, 29–30
- collagen interactions with, 24–25, 29–30
- as gel system, 29
 - nutrient and water transportation and, 29–30
- core protein molecule of, 11
- degradation of, 17
- in dermis, 26
- disease states and, 16, 26
- elastin and, 55
- in fibrous plaques, 109, 110
- in glial cells, 20
- hyaluronic acid-binding region on, 11–13
- hyaluronic acid interaction with, 37–39
- hydrodynamic volumes relative to dry volumes, 21–22
- as ion exchange resin, 22–23
 - ion transport and, 22–23
- keratan sulfate region of, 13–14
- link protein and, 12–13
- lipoprotein interaction with, 25
- mannose-rich asparagine linked glycopeptide, 14
- monomer spacing on, 13
- nasal septa, 34
- new moieties in structure of, 14
- nonaggregating, 16–17
- in nucleus pulposus, 18
- oligosaccharides and, 14–15
- in ovarian follicular fluid, porcine, 20
- physiologic function in connective tissues, 21–28
- in platelets, 20
- proteolytic enzyme digestion and, 12
- purification of, 9–21
- initial, 31–32
 - second gradient, 32–34
 - technique of, 9–10
- regions of, organization into, 11
- in Rhesus monkey corneal stroma, 19
- steric exclusion phenomenon and, 25–26
- structural analysis of, 11–16
- structures of, 5–7
- sulfated; *see specific types of sulfated proteoglycans*
- Swarm rat chondrosarcoma, 34, 54
- synthesis of, 16–17, 54–55
- types of, 17
- ultrastructural features of, 181
- water interaction with, 26–28
- see also Glycosaminoglycans; specific types of proteoglycans*
- Proteolytic enzyme digestion, 12, 114
- atherosclerosis and, 149
- of elastase, 253–256
- alveolar macrophage, 254–256
 - neutrophil, 253–254
- of elastic fibers, 238–239
- emphysema treatment with, 195; *see above of elastase*
- Pseudo-elastica, 271, 275
- Puchtler, Dr. Holde, 337–344
- Pulmonary emphysema; *see Emphysema*
- Pulmonary fibrosis, interstitial, 197–208
- biochemical studies of, 197–198
 - bleomycin-induced, 199, 204, 205
 - cadmium-induced, 204
 - collagen and, 198–201, 205
 - connective tissue composition and pulmonary function in, 201–208
 - contradictory morphologic findings on, 201
 - etiology of, 197
 - histochemical studies of, early, 197–198
 - pathologic process of, 197
 - radiation-induced, 204
- Pulmonary function
- connective tissue composition and, 201–208
 - volume-pressure relations in, 204–205
- See also Emphysema; Lungs; Pulmonary fibrosis, interstitial*
- Quantitation techniques for histological sections; *see* Histological sections, quantitation techniques for**
- Radiation-induced interstitial pulmonary fibrosis, 204**
- Radioautography, 100, 102**
- Resorcin-fuchsin stain, 270–275**

- Resorcin-fuchsin stain (*cont.*)
 collagen binding of, 271–273, 287–291
 elastin, specificity for, 271
- Reticulum fibers
 dye binding by, 290–291
 elastica stain uptake by, 272
 silver impregnation staining methods
 for, 289–290
- Sampling, 84–85
 histological section quantitation,
 procedures in, 70–71
 problems in, 215
- Schwalbe's sheaths, 282–284, 286; solvent
 dyeing of, 307–308
- Section thickness, histological, 66–67, 82–
 84
- Setnikar-Mead theory, 190, 194–195
- Silver impregnation staining methods,
 289–290
- Skin; *see* Dermis
- Smoke
 elastin degradation and, 259
 elastin synthesis and, 256–257
 emphysema and, 261
- Smooth muscle cells, migration theory of,
 297–298
- Solvent dyeing, application of, 304–308
- Solvent dyes, 330–331
- Solvents, organic, 300–304
- Staining techniques
 aldehyde-fuchsin, 275–276
 for artery walls and arterial lesions,
 differential, 59–60
 for collagen fibers, 178
 combination, 303–304
 definition of stains in, 270
 effects of, 80–81
 for elastic fibers, 178, 218
 elastica; *see* Elastica stains
 for elastin cores, 280–284
 in fluorescence microscopic distinction
 between elastin and collastin, 279–
 280
 fluorescent stains in, 331–332
 histologic section thickness and, 66–67
 lipids and, 102
 for myelin sheaths, 278–279
 new, 299–308
 orcein, 273–275, 300
 phosphomolybdic acid method, 279–
 280, 331–332
 projections onto digitizer plate and,
 81
 Puchtler's contribution to, 337–344
 resorcin-fuchsin; *see* Resorcin-fuchsin
 stain
 Schwalbe's sheaths, 282–284
 silver impregnation methods, 289–290
 solvent dyeing, 300–308
 in stereology, ideal, 81
 trichrome technic, 291
 Verhoeff's iron hematein, 276–279, 309
 Weigert-Van-Gieson, 59, 67, 80
see also Elastica stains
- Standard deviations and surface
 measurement methods, 73–79
- Static transpulmonary pressure,
 calculation of, equation for, 183
- Steric exclusion phenomenon, 25–26
- Stereology
 advantages of, 58–59
 assumptions of, 76–78, 82–83
 chemical determination compared
 with, 86–88
 principles of, 57–59, 61–66
 section thickness in, 82–84
 stains for, ideal, 81
- Sulfonated dyes, 301–302
- Surface measurement methods, 73–79;
 standard deviations in, 85
- Swarm rat chondrosarcoma
 proteoglycans, 34, 54–55
- Textile dyeing, 300
- Thickness of histologic section, 66–67,
 82–84
- Tobacco smoke
 elastin degradation and, 259
 elastin synthesis and, 256–257
 emphysema and, 261
- Trichrome staining technics, 291
- Tropoelastin, 228, 229, 234
 amount of, 245
 ratio of two, 236–237
- Trypsin, 12, 228
- Tryptic peptides, large, 229–230

- Verhoeff's iron hematein stain, 276–279, 309
- Vinblastine, 135
- Volume-pressure relations of lungs; *see*
Lungs, volume-pressure relations of
- Water**
proteoglycan interaction with, 26–28
- transportation, 29–30
- Weigert-Van-Gieson staining technique, 59, 67, 80
- Xyloxytransferase, 7–8
- Zinc deficiency, 29